Valuation : Starpharma Holdings Limited

Market Cap 336M 241M 208M 197M 178M 334M 23.03B 2.34B 898M 11.72B 906M 886M 37.03B P/E 2027 *
353x
P/E 2028 * 24.3x
Enterprise Value 290M 208M 179M 170M 154M 289M 19.87B 2.02B 775M 10.11B 781M 764M 31.94B EV / Sales 2027 *
12.1x
EV / Sales 2028 * 7.41x
Free-Float
70.11%
Yield 2027 *
-
Yield 2028 * -
1 day-10.19%
1 week-6.62%
Current month-2.08%
1 month+1.44%
3 months+3.68%
6 months+76.25%
Current year+95.83%
1 week 0.7
Extreme 0.705
0.83
1 month 0.7
Extreme 0.695
0.83
Current year 0.33
Extreme 0.33
0.83
1 year 0.12
Extreme 0.12
0.83
3 years 0.08
Extreme 0.082
0.83
5 years 0.08
Extreme 0.082
1.5
10 years 0.08
Extreme 0.082
2.52
Manager TitleAgeSince
Chief Executive Officer - 08/01/2024
Director of Finance/CFO - 03/04/2023
Human Resources Officer - 01/06/2022
Director TitleAgeSince
Chairman 81 13/06/2014
Director/Board Member 55 01/03/2020
Director/Board Member - 01/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/26 Buy

Chairman

350,001 0.0734%
11/08/26 Buy

Director

22,741 0.0048%
11/08/26 Buy

Chief Executive Officer

16,667 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
-10.19%-6.62%+487.50%+442.31% 241M
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -1.67%-5.84%+68.62%+80.54% 350.5B
Weighted average by Cap. -0.51%-4.42%+30.99%+54.97%

Financials

2027 *2028 *
Net sales 24M 17.21M 14.83M 14.04M 12.73M 23.88M 1.64B 167M 64.14M 837M 64.64M 63.23M 2.64B 37.5M 26.9M 23.17M 21.94M 19.89M 37.31M 2.57B 261M 100M 1.31B 101M 98.79M 4.13B
Net income 1.2M 861K 742K 702K 636K 1.19M 82.22M 8.34M 3.21M 41.83M 3.23M 3.16M 132M 14.7M 10.54M 9.08M 8.6M 7.8M 14.63M 1.01B 102M 39.28M 512M 39.6M 38.73M 1.62B
Net Debt -46.2M -33.13M -28.55M -27.03M -24.5M -45.97M -3.17B -321M -123M -1.61B -124M -122M -5.09B -58.4M -41.88M -36.09M -34.17M -30.97M -58.11M -4B -406M -156M -2.04B -157M -154M -6.43B
Logo Starpharma Holdings Limited
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.
Employees
50
Date Price Change Volume
11/09/26 A$0.7050 -10.19% 3,969,078
10/09/26 A$0.7850 -3.09% 1,914,746
09/09/26 A$0.8100 0.00% 2,866,972
08/09/26 A$0.8100 +1.89% 2,108,483
07/09/26 A$0.7950 +5.30% 3,723,427
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7050AUD
Average target price
1.250AUD
Spread / Average Target
+77.30%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!